Variety of qualified patients: CDEC talked over the uncertainty in the volume of clients with moderately severe to extreme hemophilia B in Canada suitable for etranacogene dezaparvovec. Clinical professionals consulted by CADTH indicated that some sufferers who're categorized as getting mild or average ailment could possibly have a significant blee